603
Participants
Start Date
March 4, 2013
Primary Completion Date
May 1, 2015
Study Completion Date
December 13, 2023
AZD9291
Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
Research Site, Tainan City
Research Site, Kogarah
Research Site, Heidelberg
Research Site, Nedlands
Research Site, Seoul
Research Site, Taipei
Research Site, Orbassano
Research Site, Genova
Research Site, Madrid
Research Site, Charlotte
Research Site, Atlanta
Research Site, Nashville
Research Site, Seville
Research Site, Saint-Herblain
Research Site, Essen
Research Site, Cologne
Research Site, Pierre-Bénite
Research Site, Houston
Research Site, Aurora
Research Site, Villejuif
Research Site, Würzburg
Research Site, Boston
Research Site, Boston
Research Site, Roma
Research Site, Chiba
Research Site, Fukuoka
Research Site, Fukuoka
Research Site, Habikino-shi
Research Site, Hirakata-shi
Research Site, Hiroshima
Research Site, Kanazawa
Research Site, Kashiwa
Research Site, Kobe
Research Site, Matsuyama
Research Site, Okayama
Research Site, Shinjuku-ku
Research Site, Sunto-gun
Research Site, Takatsuki-shi
Research Site, Yokohama
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Madrid
Research Site, Manchester
Research Site, Newcastle upon Tyne
Lead Sponsor
AstraZeneca
INDUSTRY